Harrow (HROW) shares soared 11.4% in the last trading session to close at $34.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.7% gain over the past four weeks.The sudden rise in the share price of Harrow can be attributed to the positive investor mindset regarding the continued sales growth of its innovative opthalmic pharmaceutical products in the North American market, which is expected to further boost shareholder value. ...

Astronics Corporation (ATRO) shares rallied 16.2% in the last trading session to close at $36.11. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 13.2% loss over the past four weeks.The latest uptick in ATRO’s share price can be attributed to a recent upgrade made in this stock’s rating. Notably, Truist Securities upgraded Astronics from Hold to Buy and raised its price target to $49.00 from $32.00. This comp ...

Core Viewpoint - Ardmore Shipping (ASC) shows potential for upside based on Wall Street analysts' price targets, with a mean target of $13.17 indicating a 25.7% upside from the current price of $10.48 [1] Price Targets and Estimates - The average price target consists of three estimates ranging from a low of $12.50 to a high of $14.00, with a standard deviation of $0.76, suggesting a consensus among analysts [2] - The lowest estimate indicates a 19.3% increase, while the highest suggests a 33.6% upside [2] - Analysts' agreement on earnings estimates is a strong indicator of potential stock performance, with positive revisions correlating with price movements [4][11] Analyst Behavior and Price Target Reliability - Solely relying on price targets for investment decisions may not be prudent due to historical inaccuracies in analysts' predictions [3][7] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated expectations [8] - A low standard deviation in price targets indicates strong agreement among analysts, which can serve as a starting point for further research [9] Earnings Estimates and Zacks Rank - ASC has seen a positive trend in earnings estimate revisions, with a 16.2% increase in the Zacks Consensus Estimate over the past 30 days [12] - The company holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While price targets may not be entirely reliable, the direction they imply can be a useful guide for potential stock movement [14]

Group 1 - CRISPR Therapeutics AG (CRSP) has an average brokerage recommendation (ABR) of 1.88, indicating a consensus between Strong Buy and Buy based on 27 brokerage firms' recommendations [2] - Out of the 27 recommendations, 15 are classified as Strong Buy, accounting for 55.6%, while one is classified as Buy, accounting for 3.7% [2] - Despite the positive ABR, caution is advised as studies show limited success of brokerage recommendations in predicting stock price increases [5][10] Group 2 - Brokerage analysts tend to exhibit a strong positive bias in their ratings due to vested interests, with five Strong Buy recommendations for every Strong Sell [6][10] - The Zacks Rank, a proprietary stock rating tool, is highlighted as a more reliable indicator of near-term price performance, based on earnings estimate revisions [8][11] - The Zacks Consensus Estimate for CRISPR Therapeutics remains unchanged at -$5.54, suggesting the stock may perform in line with the broader market [13][14] Group 3 - The Zacks Rank for CRISPR Therapeutics is currently 3 (Hold), indicating a more cautious stance compared to the Buy-equivalent ABR [14] - The ABR is not always up-to-date, while the Zacks Rank reflects timely earnings estimate revisions, making it a more current indicator of future price movements [12]

Wall Street analysts expect Netflix (NFLX) to post quarterly earnings of $7.05 per share in its upcoming report, which indicates a year-over-year increase of 44.5%. Revenues are expected to be $11.05 billion, up 15.6% from the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 0.3% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Prior to a ...

Core Viewpoint - Abbott (ABT) is expected to report quarterly earnings of $1.25 per share, reflecting a 9.7% increase year-over-year, with revenues projected at $11.07 billion, a 6.7% increase compared to the previous year [1]. Earnings Estimates - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock performance [2]. Key Metrics Forecast - Analysts predict 'Net sales- Nutrition' to reach $2.24 billion, indicating a 4.3% increase from the prior year [4]. - The consensus for 'Net sales- Medical Devices- Diabetes Care' is $1.94 billion, reflecting a 17.5% year-over-year change [4]. - 'Net sales- Diagnostics' is expected to reach $2.22 billion, showing a 1% increase from the previous year [4]. - 'Net sales- Established Pharmaceuticals' is forecasted at $1.37 billion, a 6.1% increase year-over-year [5]. - 'Net sales- Diagnostics- U.S.' is estimated at $832.19 million, indicating a 2.5% increase [5]. - 'Net sales- Diagnostics- International' is projected to be $1.38 billion, reflecting a 0.1% increase [5]. - 'Net sales- Nutrition- International' is expected to reach $1.26 billion, a 3.5% year-over-year change [6]. - 'Net sales- Nutrition- U.S.' is forecasted at $985.20 million, indicating a 5.6% increase [6]. - 'Net sales- Medical Devices- Neuromodulation- International' is estimated at $53.47 million, reflecting a 4.8% increase [7]. - 'Net sales- Medical Devices- Rhythm Management- U.S.' is projected at $312.05 million, indicating a 6.9% increase [7]. - 'Net sales- Medical Devices- Rhythm Management- International' is expected to reach $334.64 million, reflecting a 6.2% year-over-year change [8]. - 'Net sales- Medical Devices- Structural Heart- U.S.' is forecasted at $304.28 million, indicating a 17.9% increase [8]. Stock Performance - Abbott shares have decreased by 2.7% over the past month, contrasting with the Zacks S&P 500 composite's 4% increase, but the company holds a Zacks Rank 2 (Buy), suggesting expected outperformance in the near term [8].

Core Viewpoint - Western Alliance (WAL) is expected to report a quarterly earnings per share (EPS) of $2.02, marking a 15.4% increase year-over-year, with revenues projected at $848.1 million, reflecting an 8.5% increase compared to the same period last year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 1.3% over the past 30 days, indicating a reassessment by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Key Metrics Projections - Analysts predict a 'Net Interest Margin' of 3.4%, down from 3.6% in the same quarter last year [5]. - The estimated 'Efficiency Ratio' is 58.5%, compared to 62.3% in the same quarter of the previous year [5]. - 'Average Balance - Total interest earning assets' is forecasted to reach $79.16 billion, up from $73.87 billion year-over-year [5]. Income Projections - 'Total non-interest income' is expected to be $138.64 million, an increase from $115.20 million in the same quarter last year [6]. - 'Service charges and fees' are projected at $39.00 million, significantly higher than the $10.80 million reported a year ago [6]. - 'Net interest income' is anticipated to reach $689.27 million, compared to $656.60 million in the same quarter last year [7]. - 'Net gain on loan origination and sale activities' is expected to be $59.48 million, up from $46.80 million year-over-year [7]. - 'Other non-interest income' is projected at $15.06 million, compared to $8.10 million last year [8]. - 'Net loan servicing revenue' is expected to be $24.72 million, down from $38.10 million in the same quarter last year [8]. Stock Performance - Shares of Western Alliance have increased by 18.5% over the past month, outperforming the Zacks S&P 500 composite, which rose by 4% [8].

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying stocks that can fulfill their growth potential is challenging due to associated risks and volatility [1] Group 1: Company Overview - Orion OYJ Unsponsored ADR (ORINY) is identified as a promising growth stock with a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 5.2%, but projected EPS growth for this year is expected to be 30.2%, significantly higher than the industry average of 15.2% [4] Group 2: Financial Metrics - Orion OYJ's year-over-year cash flow growth is reported at 57.5%, which surpasses the industry average of 3.2% [5] - The company's annualized cash flow growth rate over the past 3-5 years is 9.7%, compared to the industry average of 6.7% [6] Group 3: Earnings Estimates - There has been a positive trend in earnings estimate revisions for Orion OYJ, with the Zacks Consensus Estimate for the current year increasing by 26.2% over the past month [8] - The combination of a Growth Score of B and a Zacks Rank 1 indicates that Orion OYJ is a potential outperformer and a solid choice for growth investors [10]

Global-e Online Ltd. (GLBE) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked ...

Core Viewpoint - Airbus Group has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][4]. Earnings Estimates and Stock Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate reflecting EPS estimates from sell-side analysts [2][3]. - The recent upgrade for Airbus Group suggests an improvement in its earnings outlook, which could lead to increased buying pressure and a rise in stock price [4][6]. Impact of Earnings Estimate Revisions - There is a strong correlation between changes in earnings estimates and near-term stock price movements, with institutional investors using these estimates to assess fair value [5][7]. - The Zacks Rank system effectively utilizes earnings estimate revisions to classify stocks, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. Specifics on Airbus Group's Earnings - For the fiscal year ending December 2025, Airbus Group is expected to earn $1.82 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 6.4% over the past three months [9]. Conclusion on Zacks Rating System - The Zacks rating system maintains a balanced approach, with only the top 5% of stocks receiving a "Strong Buy" rating, indicating superior earnings estimate revisions and potential for market-beating returns [10][11].